Filamentous bacteriophages expressing OVA antigen and conjugated to α-GalCer enhanced OVA-specific CD8+ T cell responses when administered in vivo, and, in the B16.OVA model, intra-tumoural administration delayed tumour outgrowth and improved survival [110]. Here, CD8A is linked to neoplasm.